Compare Enovix Corporation (ENVX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Enovix Corporation trades at $2.53 (market cap $549.72M), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 18.4× Enovix Corporation's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| ENVX | XBI | |
|---|---|---|
Market Cap | $549.72M | $10.11B |
Volume | 6,635,687 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $13.19 | $169.55 |
52-Week Low | $2.50 | $104.99 |
Typical Hold Time | 11 Days | 37 Days |
Enterprise Value | $611.42M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.55, down 5.56% on the day, reflecting a bearish technical outlook with significant selling pressure indicated by moving averages and oscillators. Fundamentally, the company is in a high-growth, pre-profitability phase, with revenue growing to $36 million in 2026 but net losses widening to -$170 million. Recent news is dominated by a sudden CEO resignation in August 2026, though the company reaffirmed its strategy and operational guidance.
The investment case hinges on the company's advanced battery technology and expansion plans, particularly in the defense and drone sectors, against a backdrop of persistent cash burn and high execution risk. Analyst consensus remains bullish with a $10.75 price target, but the stock faces near-term volatility from leadership uncertainty and the challenging path to profitability.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
